Microvesicles derived from cell protoplast and use thereof
AssigneeAeon Medix Inc.
InventorsYong Song GHO, Su Chul JANG, Yoon Keun KIM, Oh Youn KIM
Life of this patent
Estimating the term…
Abstract
The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.
Claims19
A method of making a pharmaceutical composition, the method comprising:
- providing bacteria comprising a cell wall, an antigenic protein and an extracellular domain;
- removing the cell wall from the bacteria to provide a cell-wall-deficient composition that is deficient of the cell wall and comprises the antigenic protein and the extracellular domain;
- processing the cell-wall-deficient composition to produce microvesicles comprising the antigenic protein and the extracellular domain, wherein the resulting microvesicles comprise a mixture of first type microvesicles with the extracellular domain on their outer surfaces and second type microvesicles with the extracellular domain on their inner surfaces;
- isolating, from the mixture, at least part of the first type microvesicles with the extracellular domain on their outer surfaces;
- and
- formulating a pharmaceutical composition comprising the isolated microvesicles with the extracellular domain on their outer surfaces.
Dependencies are inferred from the claim text.